KYMERA THERAPEUTICS, INC. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-05: Disclosure Non Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-05: Disclosure Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
- 2026-04-30: Disclosure Material Terms Of Trading Arrangement; Period 2026-01-01..2026-03-31; Value Item 5. Oth er Information. The following table discloses any officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) or director who adopted a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulat….
- 2026-04-30: Disclosure Rule10b51Arr Adopted; Period 2026-01-01..2026-03-31; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-05 10-Q | Non Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-08-05 10-Q | Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-04-30 10-Q | Material Terms Of Trading Arrangement | 2026-01-01..2026-03-31 | Item 5. Oth er Information. The following table discloses any officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) or director who adopted a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulat… | |
| 2026-04-30 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-04-30 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-04-30 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-04-30 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-04-29 DEF 14A | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-29 DEF 14A | Pay versus Performance Table | 2025-01-01..2025-12-31 | Pay Versus Performance The following table reports the compensation for Dr. Mainolfi (our Principal Executive Officer, or PEO) and the average compensation of the other Named Executive Officers (Other NEOs) as reported in the Summary Compensation Table in our proxy statements for the past five fisca… | |
| 2026-04-29 DEF 14A | Adjustment To PEO Compensation Footnote | 2025-01-01..2025-12-31 | The PEO Summary Compensation Table to compensation actually paid (or CAP) reconciliation is summarized in the following table: Year Summary Compensation Table Total Summary Compensation Table Equity Change in Value of Awards Unvested at FYE Change in Value of Prior Years’ Awards that Vested in FY Ch… | |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$7.32M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $24.07M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$239.36K |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $2.79M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $0.00 |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | -$14.21M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $12.09M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $3.58M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $2.85M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo | 2024-01-01..2024-12-31 | $0.00 |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | -$8.59M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $4.37M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | -$40.00K |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $999.06K |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $0.00 |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | -$5.95M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | -$13.73M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | -$12.95M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | $737.34K |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | $0.00 |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | -$10.62M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $10.81M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | -$1.76M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $2.61M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $0.00 |
| 2026-04-29 DEF 14A | Named Executive Officers Footnote | 2025-01-01..2025-12-31 | The amounts reported represent the average of the amounts reported for the Other NEOs, in the “Total” column of the Summary Compensation Table in each applicable year. The names of each of the named executive officers included for purposes of calculating the average amounts were (i) for 2025 Bruce J… | |
| 2026-04-29 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2025-01-01..2025-12-31 | The average Other NEO Summary Compensation Table to CAP reconciliation is summarized in the following table: Year Summary Compensation Table Total Summary Compensation Table Equity Change in Value of Awards Unvested at FYE Change in Value of Prior Years’ Awards that Vested in FY Change in Value of A… | |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$3.18M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $9.39M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$126.16K |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $229.38K |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $0.00 |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | -$4.64M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $4.22M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $804.72K |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $733.69K |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2024-01-01..2024-12-31 | $0.00 |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | -$3.78M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $2.43M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $59.83K |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $141.53K |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $0.00 |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$1.42M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$2.44M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$3.22M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $268.47K |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $0.00 |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | -$2.83M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $2.59M |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | -$713.57K |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $677.26K |
| 2026-04-29 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | -$2.90M |
| 2026-04-29 DEF 14A | Peer Group Issuers Footnote | 2025-01-01..2025-12-31 | Peer group total shareholder return, or TSR, reflects the Nasdaq Biotechnology Index for all fiscal years disclosed, which aligns with the peer group used in our Annual Report on Form 10-K for each of these years. | |
| 2026-04-29 DEF 14A | Compensation Actually Paid Vs Company Selected Measure | 2025-01-01..2025-12-31 | Description of the Relationship Between Compensation Actually Paid and Selected Performance Metrics As described above in the section titled “Compensation Discussion and Analysis,” our compensation program is designed to attract and retain high-performing talent in our industry, motivate our executi… | |
| 2026-04-29 DEF 14A | Compensation Actually Paid Vs Net Income | 2025-01-01..2025-12-31 | Compensation Actually Paid and Net Loss Because we are not a commercial-stage company, we did not have any revenue during the periods presented, other than the recognition of non-cash deferred revenue associated with our collaboration agreements. Consequently, our company has not historically looked… | |
| 2026-04-29 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2025-01-01..2025-12-31 | PEO and Other NEO Compensation Actually Paid and Company Total Shareholder Return (“TSR”) Equity awards are the largest component of our executive compensation program, representing no less than 80% of the target total compensation for each of our executives. Therefore, TSR has a significant impact … | |
| 2026-04-29 DEF 14A | Total Shareholder Return Vs Peer Group | 2025-01-01..2025-12-31 | TSR for our peer group is based on the Nasdaq Biotechnology Index (XNBI), which reflects the company’s industry sector and is also the peer group used in our Annual Report on Form 10-K. We outperformed our peers during 2021, reflecting the substantial progress towards our stated goals and the achiev… | |
| 2026-04-29 DEF 14A | Award Timing MNPI Disclosure | 2025-01-01..2025-12-31 | Policies and Practices Regarding Grants of Equity Awards Our Compensation Committee and board of directors generally make equity grants on regularly scheduled dates, which includes grants in March for executive officers and other employees and following our annual meetings of shareholders in June fo… | |
| 2026-04-29 DEF 14A | Award Timing Method | 2025-01-01..2025-12-31 | The board of directors or Compensation Committee may change any regularly scheduled grant date if the board of directors or Compensation Committee determines that making grants on such date would not be in the company’s best interest. Equity grants may also be made on other dates in connection with … | |
| 2026-04-29 DEF 14A | Award Timing MNPI Considered | 2025-01-01..2025-12-31 | No | |
| 2026-04-29 DEF 14A | Award Timing Predetermined | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-29 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2025-01-01..2025-12-31 | No | |
| 2026-02-26 10-K | Material Terms Of Trading Arrangement | 2025-10-01..2025-12-31 | The following table discloses any officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) or director who entered into, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regula… | |
| 2026-02-26 10-K | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-02-26 10-K | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |